| eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer |
2019-11-07 |
| eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners |
2019-11-07 |
| Artios Pharma–Univ Texas: ATR inhibitors, 201911– license excl ww to small-molecula ATR inhibitor programme from MD Anderson + ShangPharma Innovation |
2019-11-06 |
| Greenough–KDM Communications: investment, 201911 merger combination to provide transatlantic PR services |
2019-11-06 |
| Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA |
2019-11-06 |
| Vifor Pharma–Evotec: drug r+d, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w |
2019-11-06 |
| Poxel–IPF Partners: credit, 201911–201412 bond loan up to €30m in three tranches 11/19 + 3/20 + 12/21 |
2019-11-05 |
| Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners |
2019-11-04 |
| Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners |
2019-11-04 |
| Fitbit–Alphabet: investment, 201911– acquisition of Fibit Inc by Google LLC for $7.35/share in cash valuing Fibtit at $2.1b ANNOUNCED |
2019-11-01 |
| Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma |
2019-10-31 |
| genOway–Institut Pasteur: transgenic anmials, 201910– license extension from IP + Cellectis to genOway to take legal actions against infringement |
2019-10-30 |
| Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie |
2019-10-29 |
| Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S |
2019-10-29 |
| Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S |
2019-10-29 |
| Centogene–SEVERAL: investment, 201910– IPO $60m with 4m+600k comon shares at $14-$16/share at Nasdaq Global Market ANNOUNCED |
2019-10-28 |
| i-Dositecno–SP Industries: investment, 201910 acquisition of assets of i-Dositecno by SP Industries |
2019-10-28 |
| SMS-Oncology–Cato Research: investment, 201910 merger €na |
2019-10-28 |
| Pepticom–Chartered Group: investment, 201910 Series A investment of $5m by the Chartered Group |
2019-10-24 |
| OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
| Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m |
2019-10-22 |
| MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion |
2019-10-22 |
| MCG Motion Capture–Biotech Alliances International: investment banking, 201910– service excl for planned $15m Series A Round of MCG |
2019-10-22 |
| MCG Motion Capture–SEVERAL: investment, 201910– PLANNED financing round Series A $15m |
2019-10-22 |
| Arcutis Biotherapeutics–HBM: investment, 201910 financing round Series C totalling $94.5m incl new + lead investor HBM Healthcare Investments |
2019-10-21 |
| Arcutis Biotherapeutics–OrbiMed: investment, 201910 financing round Series C totalling $94.5m incl existing + co-investor OrbiMed |
2019-10-21 |
| Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments |
2019-10-21 |
| Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN |
2019-10-21 |
| Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal |
2019-10-21 |
| Plexium–Merck (DE): investment, 201910 financing round Series A totalling $28m incl co-investor M Ventures |
2019-10-17 |
| Plexium–SEVERAL: investment, 201910 financing round Series A $28m co-led by DCVC Bio + The Column Group |
2019-10-17 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| Adaptate Biotherapeutics–Abingworth: investment, 201910 investment by Abingworth + Takeda facilitating spin-out of Adaptate from GammaDelta Tx |
2019-10-16 |
| Adaptate Biotherapeutics–SEVERAL: investment, 201910 spin-out from GammaDelta Therapeutics with investment from Abingworth & Takeda Pharmaceutical |
2019-10-16 |
| Adaptate Biotherapeutics–Takeda: investment, 201910 investment by Abingworth + Takeda with time-limited option to acquire Adatpate for Takeda |
2019-10-16 |
| Amarna Therapeutics–Flerie Invest: investment, 201910 financing round totalling €10m incl lead investor Flerie Invest AB + incl RVO innovation credit |
2019-10-16 |
| Amarna Therapeutics–Netherlands (govt): credit, 201910 financing round totalling €10m incl substantial innovation credit from RVO.nl |
2019-10-16 |
| Amarna Therapeutics–PERSON: investment, 201910 financing round totalling €10m incl existing + co-investor Pim Berger + incl RVO innovation credit |
2019-10-16 |
| Amarna Therapeutics–SEVERAL: investment, 201910 financing round €10m led by Flerie Invest AB + incl innovation credit from RVO.nl |
2019-10-16 |
| Healx–Amadeus Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Amadeus Capital Partners |
2019-10-16 |
| Healx–Atomico: investment, 201910 financing round Series B totalling $56m incl new + lead investor Atomico |
2019-10-16 |
| Healx–Balderton Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Balderton Capital |
2019-10-16 |
| Healx–btov Partners: investment, 201910 financing round Series B totalling $56m incl new + co-investor btov Partners |
2019-10-16 |
| Healx–Global Brain: investment, 201910 financing round Series B totalling $56m incl new + co-investor Global Brain |
2019-10-16 |
| Healx–Intel: investment, 201910 financing round Series B totalling $56m incl new + co-investor Intel Capital |
2019-10-16 |
| Healx–PERSON: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Jonathan Milner |
2019-10-16 |
| Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico |
2019-10-16 |
| Abalos Therapeutics–Boehringer: investment, 201910 financing round Series A totalling €12m invl co-lead investor BIVF |
2019-10-15 |
| Abalos Therapeutics–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling €12m incl co-investor HTGF |
2019-10-15 |
| Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK |
2019-10-15 |
| Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr |
2019-10-15 |
| Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr |
2019-10-15 |
| Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-15 |
| CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP |
2019-10-15 |
| Mogrify–24Haymarket: investment, 201910 financing round Series A first closing totalling $16m incl existing + co-investor 24Haymarket |
2019-10-14 |
| Mogrify–Ahren Innovation Capital: investment, 201910 financing round Series A first closing totalling $16m incl existing + lead investor Ahren |
2019-10-14 |
| Mogrify–Parkwalk Advisors: investment, 201910 financing round Series A first closing totalling $16m incl new + co-investor Parkwalk |
2019-10-14 |
| Mogrify–SEVERAL: investment, 201910 financing round Series A first closing $16m led by existing investor Ahren Innovation Capital |
2019-10-14 |
| Mogrify–Univ Bristol: investment, 201910 financing round Series A first closing totalling $16m incl new + co-investor Univ Bristol Enterprise Fund III |
2019-10-14 |
| Biocon–Evotec: biosimilars, 201910– license €na to Biocon Biologics for pre-clinical biosimilar asset of Just-Evotec Biologics |
2019-10-10 |
| FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck |
2019-10-10 |
| Ra Pharmaceuticals–UCB: investment, 201910– acquisition $2.5b in cash for $48/share incl acquired net cash of $315m ANNOUNCED |
2019-10-10 |
| Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health |
2019-10-09 |
| D.I. Biotech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Korea by D.I. Biotech Ltd |
2019-10-09 |
| Imperial Life Sciences–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in India by Imperial |
2019-10-09 |
| Kiko Tech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Japan by Kiko Tech Co Ltd |
2019-10-09 |
| N-Side–Sciad Communications: public relations, 201910 service existent by Sciad |
2019-10-09 |
| Novo Group–Bluebird Bio: gene therapy, 201910–202209 collab r+d 3y utilising megaTAL technology to develop hemophilia A gene therapies |
2019-10-09 |
| Optec (RU)–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Russia by Optec LLC |
2019-10-09 |
| Parexel–Roivant: healthcare informatics, 201910– collab with Datavant multi-year strategic alliance integration of real-world with clinical trial data |
2019-10-09 |
| Trio Biotech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in China by Trio Biotech Co Ltd |
2019-10-09 |
| Unimed Healthcare–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Taiwan by Unimed |
2019-10-09 |
| Bayer–RIKEN: drug discovery, 201910– strategic collaboration incl drug target discovery of Bayer Open Innovation Center Japan + RIKEN Innovation |
2019-10-08 |
| GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies |
2019-10-08 |
| Merck (US)–4D Pharma: microbiomic treatments, 201910– collab r+d Live Biotherapeutics as vaccines |
2019-10-08 |
| Vivoryon–MC Services: public relations, 201910 service existent by MC Services |
2019-10-08 |
| Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG |
2019-10-08 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| 4SC–SEVERAL: investment, 201910 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights |
2019-10-07 |
| 4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS |
2019-10-07 |
| Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity |
2019-10-07 |
| Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w |
2019-10-07 |
| MiroBio–Advent Venture Partners: investment, 201910 financing round Series A totalling £27m incl co-investor Advent Life Sciences |
2019-10-07 |
| MiroBio–GSK: investment, 201910 financing round Series A totalling £27m incl co-investor SR One |
2019-10-07 |
| MiroBio–Samsara Biocapital: investment, 201910 financing round Series A totalling £27m incl co-lead investor Samsara Biocapital |
2019-10-07 |
| MiroBio–SEVERAL: investment, 201910 financing round Series A £27m co-led by Oxford Sciences Innovation + Samsara Biocapital |
2019-10-07 |
| MiroBio–Univ Oxford: investment, 201910 financing round Series A totalling £27m incl co-lead investor Oxford Sciences Innovation |
2019-10-07 |
| Rentschler–Sumitomo: biologics contract manufacturing, 201910– collab expansion SPI supports marketing + delivery of Rentschler CDMO services in Japan |
2019-10-04 |
| Aeovian Pharmaceuticals–Apollo Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo Health Ventures |
2019-10-03 |
| Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec |
2019-10-03 |
| Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments |
2019-10-03 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lsus-life-sciences-usa-com.jpg)
Date![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
